How The EU Must Address Regulatory Hurdles Deterring Medtech Investors
The EU Should Assess Certain Successful US Regulatory Strategies
In the EU, developers struggle to tell potential investors how many trials a device might require, the potential duration or associated costs. Tom Melvin explains how to tackle these issues in a third piece* based on a recent interview.
